Rockfield Medical After the EIC Accelerator: Tube Feeding, Unwired

More than a million people in Europe and the United States depend on tube feeding every day, according to the EU project that helped Rockfield Medical Devices scale up, and most are fed by an electric pump or a bag that drains by gravity. Rockfield, a start-up based at Atlantic Technological University's iHub in Galway, makes a pouch that pushes the feed by itself. It fits in a small bag, needs no battery and makes no sound. The European Innovation Council selected the company in the 8 January 2020 cut-off of the EIC Accelerator pilot with blended finance, grant plus equity, according to the Commission's list of selected companies, which names Rockfield as the only beneficiary of the project.

The grant, €1,605,012.50 towards a €2,292,875 project called MobilityPlus, was not for the pouch alone. CORDIS describes a "connected medical device for enteral feeding care that can generate, collect, analyse and transmit data", built on "nano-sensors" and the "Internet of Medical Things". Nearly four years after the project ended, the pouch is on sale in the United States and was cleared for Europe in January 2026. The connected system has not appeared.

Where Rockfield Stands Now

Rockfield is trading. The Irish company register lists it with status "Normal", with an annual return and financial statements filed on 25 August 2026, two returns of share allotments on 7 July 2026 and a change of director details on 7 September 2026, according to OpenCorporates, which mirrors the Companies Registration Office. North Data shows the same Galway address and accounts for the year to 31 December 2024 filed on 22 August 2025. The figures in those accounts are behind paywalls and could not be checked, so revenue, losses and headcount are not public. No insolvency notice was found.

On 7 January 2026 the company announced its CE mark, which allows Mobility+ to be sold across the European Union, in a release published on EIN Presswire and on its own website. Neither names the notified body or a European distributor, and no European customer has been announced since.

The commercial record so far is American. The US reimbursement code HCPCS B4148, "enteral feeding supply kit; elastomeric control fed, per day", took effect on 1 October 2023 after Rockfield applied for it, the company said. In June 2025 it signed U Deliver Medical, a US online seller of enteral feeding supplies, according to a joint release; the store page lists packs of 3, 10 and 30 single-day units at $45, $130 and $370. In April 2025 Mobility+ won the Exhibitor Innovation Award of the US National Home Infusion Association, chosen from four finalists out of more than 145 exhibitors, according to NHIA's finalist announcement and its list of winners. Sales volumes have not been disclosed.

The Technology: A Balloon Instead of a Motor

Tube-fed patients at home usually choose between three methods: a syringe pushed by hand, a bag that drains by gravity, or an electric pump that sets the rate. Pumps are accurate but heavy, noisy and need charging; gravity ties the patient to a stand. Mobility+ is a foil container holding an elastomeric pouch that is filled with formula through a syringe and then contracts, pushing the feed through tubing whose length sets the flow rate, according to the FDA's 510(k) record and its summary on Innolitics. Each unit is disposable and used for one day, holds up to 500 ml and connects with ENFit connectors to the patient's feeding tube. It is cleared for users aged two and over and for standard, not blended, formulas.

The business idea is in the CORDIS summary: switch enteral feeding from a market of capital equipment, with pumps to buy and maintain, to one of daily consumables. Rockfield's claim, repeated in its CE mark release and in NHIA's description, is to be the first to apply the principle to tube feeding.

What MobilityPlus Promised, and What CORDIS Shows

MobilityPlus ran for 30 months from 1 May 2020 to 31 October 2022. Its objective on CORDIS promised a connected system that would "lower enteral feeding healthcare costs by up to 60%" and be "the first and only solution" with "e-connectivity: enabling effective self-monitoring". The final periodic report splits the outcome in two. The pouch was "designed, developed, tested and validated to TLR8", the first elastomeric feeding device cleared by the FDA. The accessory meant to measure the feed delivered and send it to a phone and a clinical data service reached only "TLR6": its concept phase was complete and it was "ready to move into the Development Phase". Commercialisation, the report adds, was "not funded by this action".

The FDA clearance arrived at the last moment. Rockfield first filed in May 2021, then paused after the FDA asked for more biocompatibility testing at higher extraction temperatures, a body of work whose longest test took 16 weeks, according to the report. The two records differ on the dates of the resubmission: CORDIS says it was sent on 29 August 2022 and that clearance was notified on 20 October 2022, while the FDA database gives a receipt date of 6 September 2022 and a decision date of 27 October 2022. Either way, it came within days of the project's end. A second clearance, K233034 on 12 April 2024, allowed over-the-counter sale.

1. Mechanical feeding device to market readinessDeliveredValidated to TRL 8; FDA 510(k) clearance in October 2022, per CORDIS and the FDA.
2. Sensors, connectivity and data platformNot deliveredStopped at TRL 6 prototypes; neither the FDA nor the CE mark release covers a connected product, and none has been announced.
3. EU market entryLateNotified body chosen during the project; CE mark only in January 2026.
4. Healthcare costs cut by up to 60%Not shownNo cost study has been published; the second EU project lists a health economics report as a deliverable on CORDIS, but its findings are not public.
5. US commercial launchDeliveredInitial US launch reported by CORDIS; reimbursement code from October 2023 and online sales from June 2025.

The scorecard makes MobilityPlus partly delivered. The device the EIC funded exists, is cleared on both sides of the Atlantic and is sold. The feature that gave the project its title, the "connected enteral feeding healthcare system", did not reach patients, and nothing in the company's public material since 2022 mentions it.

What Came After the Grant

A second Horizon 2020 grant carried the device into production. Mobility, a Fast Track to Innovation project coordinated by Atlantic Technological University from December 2020 to November 2023, gave Rockfield €1,092,102.07 of a €2,854,935.85 EU contribution, alongside the German plastics maker Georg Menshen and SteriPack Medical Poland. Its final report records hard tooling and a qualified spout assembly machine at Menshen, a validated assembly process at SteriPack, an ISO 13485 quality system awaiting notified body audits in 2024, and "a Series A funding round" completed in October 2023. The amount and investors of that round have not been published.

Whether the EIC's equity was invested is only partly visible. Rockfield appears on the official list of EIC Fund invested companies, with a portfolio page that gives no amount or date. The investor database vcbacked lists the European Innovation Council and Enterprise Ireland as investors and a $550,000 round in July 2023, a figure that could not be confirmed elsewhere. The company register shows several capital changes since: returns of allotments in August 2024, January 2025 and twice in July 2026, and increases in authorised share capital in June 2024 and March 2025, according to the filing history.

The clinical evidence is thin but growing. A single-arm study at the Mayo Clinic, sponsored by Rockfield with Horizon 2020 named as collaborator, enrolled 19 adults from November 2023 and was stopped in November 2024 "due to difficulties in recruitment", short of the 25 planned, according to ClinicalTrials.gov. The registry adds that "no safety concerns were raised and no adverse events occurred". Patients rated everyday activities while feeding much easier after 14 days on Mobility+, though overall satisfaction barely moved, from 3.5 to 3.6 out of 5, and ease of use slipped from 3.8 to 3.5. The company has presented further posters at ASPEN, ESPEN and FNCE conferences in 2025 and 2026, as listed on its news page.

Why Europe Should Care

The EIC backed MobilityPlus as a way to cut the cost of chronic tube feeding, which the proposal said its device would lower by up to 60% by removing pumps, batteries and maintenance; that saving remains a claim. The connected half of the project would have matched the EU's data agenda: the European Health Data Space regulation, in force since 26 March 2025, is built on patients and clinicians sharing electronic health data. That is the part Rockfield did not deliver.

The sequence of approvals also says something about Europe's medical device rules. Rockfield's device was cleared in the United States in October 2022 and sold there from 2023, while its European approval, under the regulations that replaced the EU's three earlier device directives and are described by the European Commission, came in January 2026. An Irish company funded by two EU grants sold its product to American patients for more than two years before it could sell it to European ones.

The Verdict

Rockfield Medical Devices has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.